ENZ - Enzo Biochem, Inc.

NYSE - NYSE Delayed Price. Currency in USD
2.1300
+0.0300 (+1.43%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close2.1000
Open2.0800
Bid2.0000 x 1300
Ask2.1500 x 800
Day's Range2.0100 - 2.1600
52 Week Range2.0100 - 4.4600
Volume138,707
Avg. Volume103,646
Market Cap101.296M
Beta (5Y Monthly)1.09
PE Ratio (TTM)142.00
EPS (TTM)0.0150
Earnings DateDec 09, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • Business Wire

    Shareholders Support the Election of Both HDF Nominees to Enzo Board of Directors

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that, based on a preliminary vote count provided by its proxy solicitor, Enzo shareholders voted to elect HDF nominees, Fabian Blank and Peter Clemens, and Company nominee Rebecca Fischer, to the Board of Directors (the "Board") at the Company’s 2019 Annual Meeting of Shareholders (the "Annual Meeting") today.

  • Business Wire

    Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting

    Enzo Biochem (NYSE:ENZ) announced preliminary results of voting at the 2019 Annual Shareholder meeting held today.

  • Business Wire

    ISS Recommends Shareholders Vote AGAINST Enzo Proposal to Increase Size of Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that shareholders vote on the BLUE proxy card AGAINST Enzo’s proposal to amend its bylaws in order to increase the size of the Board and re-nominate Barry Weiner. Enzo’s delayed 2019 Annual Meeting of Shareholders (the "Annual Meeting") is scheduled for February 25, 2020.

  • Business Wire

    Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1‑I in a Model of Lupus

    Enzo Biochem, Inc. (NYSE:ENZ) today announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate "SK1‑I," the company’s proprietary Sphingosine Kinase 1 inhibitor, markedly reduced Lupus-associated parameters in a recognized, chemically-induced animal model of Systemic Lupus Erythematosus, commonly known as "Lupus." This treatment resulted in reductions in interferon (IFN) signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney. Significantly, SK1-I was not only effective when administered simultaneously with the chemical induction of Lupus in this model, but was also effective when administered thirty (30) days after the chemical induction of the disorder. In further confirmation that the effects of SK1-I in the Lupus model are the result of inhibiting the enzyme Sphingosine Kinase 1, the effects were mirrored by genetic deletion of the enzyme. These results suggest that SK1-I may have potential in the treatment of Lupus.

  • Benzinga

    The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

  • Business Wire

    Enzo Biochem Announces Significant Milestone with Approval of Proprietary GenFlex Platform

    Enzo Biochem, Inc. (NYSE: ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc. has received New York State approval for its CT/NG/TV tests using liquid-based cytology sample collection on its proprietary GenFlex platform. GenFlex is a commercially available sample-to-result molecular diagnostic platform that includes sample collection, sample processing, amplification and detection. The GenFlex open system delivers high-throughput, high capacity, workflow efficiency and flexibility at a much greater level of affordability than existing systems.

  • Business Wire

    Enzo Disappointed in Harbert’s Lawsuit Aimed at Disenfranchising Shareholders

    Enzo Biochem, Inc. (NYSE:ENZ) (the "Company") today disclosed that Harbert Discovery Fund, LP ("Harbert") filed a lawsuit against the Company and the members of its board of directors ("Board") in the U.S. District Court for the Southern District of New York.

  • Business Wire

    Harbert Discovery Fund Files Lawsuit Seeking to Hold Enzo Board Accountable for Acts of Entrenchment and Illegal Maneuvers

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that it has filed a complaint in the U.S. District Court for the Southern District of New York asserting direct claims against Enzo and asserting both direct and derivative claims against members of its Board of Directors (the "Board") (Case 1:20-cv-01021). The complaint alleges that Enzo has engaged in brazen acts of entrenchment and misuse of the corporate machinery in an effort to keep Barry Weiner on the Board after most of Enzo’s shareholders had voted and it had become clear that Weiner would be removed.

  • Business Wire

    Enzo Comments on Harbert’s Reaction to Providing Enzo Shareholders Additional Choices

    Enzo Biochem, Inc. (NYSE:ENZ) today commented on Harbert’s press release in reaction to Enzo’s announcement that it is providing its shareholders with additional choices:

  • Business Wire

    Harbert Discovery Fund Comments on Enzo Biochem’s Entrenchment Maneuvers

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following statement commenting on Enzo’s January 28, 2020 press release announcing the postponement of its 2019 Annual Meeting of Shareholders (the "Annual Meeting") to February 25, 2020 and proposing the potential expansion of its Board of Directors (the "Board") to seven seats from the current five.

  • Business Wire

    Enzo Biochem Proposes to Increase Size of Board and Will Appoint Additional Highly Qualified, Diverse Independent Director in Near Future

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today announced that Enzo’s board of directors ("Board") has made a series of changes to the agenda for the upcoming Annual Meeting of Shareholders of the Company ("Annual Meeting").

  • Business Wire

    Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today sent a letter to shareholders in connection with its efforts to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the "Board") at its 2019 Annual Meeting of Shareholders (the "Annual Meeting"), which will be held on January 31, 2020.

  • Business Wire

    All Three Proxy Advisory Firms Recommend Shareholders Vote FOR Change to the Board of Enzo Biochem on the Blue Card

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that Egan-Jones Proxy Services ("Egan-Jones") has recommended shareholders vote for both HDF nominees on the Blue proxy card. All three leading proxy advisors – Egan-Jones, Glass, Lewis and Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") – have now supported HDF’s case for change at Enzo.

  • Business Wire

    Enzo Biochem Comments on ISS Report

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today commented on the report Institutional Shareholder Services (ISS) issued in connection with the upcoming Annual Shareholder Meeting.

  • Business Wire

    ISS Recommends Shareholders Vote FOR the Election of Harbert Discovery Fund Nominee to Enzo Biochem Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s nominee, Fabian Blank.

  • Business Wire

    Glass Lewis Recommends Shareholders Vote For the Election of Both Harbert Discovery Fund Nominees to Enzo Biochem’s Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Glass, Lewis & Co. ("Glass Lewis"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s two highly-qualified independent nominees, Fabian Blank and Peter Clemens.

  • Business Wire

    Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

    The Board of Directors of Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund ("Harbert") regarding the Company’s significant accomplishments. The Board believes that Harbert’s campaign of disinformation is designed to divert attention from its inferior slate of underqualified nominees and weak arguments bereft of any true understanding of Enzo’s business or market. With Harbert steadfastly seeking to change 40% of the Board (which would result in only a single independent director remaining with more than a few weeks of experience on our Board), it is critical that the Company set the record straight so shareholders can make a fully informed decision at the upcoming Annual Shareholder meeting.

  • Business Wire

    Harbert Discovery Fund Releases Detailed Investor Presentation Highlighting Case for Change at Enzo Biochem

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today released a detailed investor presentation on Enzo. The presentation outlines the Company’s history of value destruction, persistent underperformance, and corporate governance issues and details HDF’s Nominees’ strategic plan to realize value at Enzo.

  • How Does Enzo Biochem, Inc. (NYSE:ENZ) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does Enzo Biochem, Inc. (NYSE:ENZ) Affect Your Portfolio Volatility?

    Anyone researching Enzo Biochem, Inc. (NYSE:ENZ) might want to consider the historical volatility of the share price...

  • Business Wire

    Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors. Her appointment as a new independent director is effective immediately and follows a search process conducted as part of Enzo’s ongoing focus on Board composition, refreshment and diversity. As part of our evaluation, the Company as a significant provider of Women’s health products and services, believes the representation of such a highly qualified woman on the Board would be a valuable contribution to it.

  • Is Enzo Biochem, Inc. (ENZ) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Enzo Biochem, Inc. (ENZ) Going To Burn These Hedge Funds ?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]